Aurobindo Pharma reported a consolidated net profit of ₹1,032 crore for Q1FY27, a 25.2% increase from ₹824 crore in the same period last year. Revenue from operations grew 16.3% year-on-year to ₹9,150 crore, driven by robust volume gains in Europe and the US, alongside new product launches. The company maintained an operating EBITDA margin of 21.0%, expanding by 60 basis points compared to Q1FY26, while generating free cash flow of US$ 98 million despite significant capital deployment for acquisitions and buybacks.

The unaudited financial results for the quarter ended June 30, 2026, were submitted to the National Stock Exchange of India Limited and BSE Limited on August 5, 2026, under Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. B. Adi Reddy, Company Secretary, signed the disclosure. An investor and analyst call was scheduled for August 6, 2026, to discuss the performance.

Financial Performance

Revenue growth was broad-based across geographies. US formulations revenue rose 8.1% year-on-year to ₹3,770 crore (US$ 399 million), supported by volume gains and ten new product launches. Europe saw a sharper 25.6% increase to ₹2,937 crore (EUR 267 million), accounting for 32.1% of consolidated revenue. Growth markets expanded by 37.7% to ₹1,063 crore (US$ 113 million). The API segment contributed ₹1,049 crore, up 14.6% year-on-year, though it faced sequential softness due to seasonal factors in antibiotics. ARV revenue remained stable at ₹330 crore.

*Operating EBITDA excludes a one-time expense of ₹43 crore related to the derecognition of lease receivables.

Cash Flow and Capital Allocation

Despite heavy capital deployment, Aurobindo Pharma generated free cash flow from business of US$ 98 million in Q1FY27. This was achieved after accounting for normal capex of US$ 40 million. The company utilized cash for the Lannett acquisition (US$ 247 million), share buybacks (US$ 85 million), and new business development capex (US$ 20 million). As of June 30, 2026, the company held a net cash position (including investments) of approximately US$ 42 million. Gross debt stood at US$ 887 million, comprising working capital loans of US$ 800 million and other term loans of US$ 87 million.

What the Numbers Show

The divergence between operating EBITDA growth (20.0%) and net profit growth (25.2%) highlights the impact of non-operating items. While operating margins expanded modestly, the bottom line benefited significantly from other income, which nearly doubled to ₹212 crore from ₹105 crore in Q1FY26, alongside a foreign exchange gain of ₹53 crore. Conversely, the one-time lease derecognition expense of ₹43 crore tempered reported EBITDA figures, though operational profitability remained robust across all key segments. Basic and diluted EPS stood at ₹17.86 per share.

Biosimilars and Contract Manufacturing Updates

CuraTeQ Biologics advanced its regulatory and commercial footprint. The company secured ANVISA GMP certification for Brazil and filed Denosumab biosimilars (FILVIZY and FUGEVY) with the EMA. Commercially, all four MHRA-approved products are now supplying in the UK, with multi-country rollouts underway in Europe and initial entries into Mexico and Algeria. TheraNym, the biologics contract manufacturing arm, inaugurated Unit 1 on June 3, 2026, with qualification activities set for November 2026. Construction on Unit 2, estimated at US$ 180 million, is scheduled to begin in October 2026.

Aurobindo Pharma has set an ambitious revenue target for its subsidiary Eugia, expecting the injectable-focused business unit to achieve $500 million in revenue by FY27. This projection underscores the company's confidence in Eugia's growth potential within the pharmaceutical sector.

Eugia Revenue Target

The company's expectations for Eugia's FY27 revenue milestone highlight the strategic importance of the subsidiary to Aurobindo Pharma's overall business portfolio. The $500 million target represents a key marker for the injectable segment's performance going forward.

Eugia operates as a dedicated injectable business under the Aurobindo Pharma umbrella, and the stated revenue expectation signals the parent company's commitment to scaling this segment. The $500 million figure serves as a forward-looking benchmark communicated by the company's management.